High-dose chemotherapy and stem-cell rescue in the treatment of high- risk breast cancer: Prognostic indicators of progression-free and overall survival

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2882-2893

  Somlo, George ^a   Doroshow, James H ^a   Forman, Stephen J ^a   Odom Maryon, Tamara ^a   Lee, Jennifer ^a   Chow, Warren ^a   Hamasaki, Victor ^a   Leong, Lucille ^a   Morgan Jr , Robert ^a   Margolin, Kim ^a   Raschko, James ^a   Shibata, Stephen ^a   Tetef, Merry ^a   Yen, Yun ^a   Simpson, Jean ^a   Molina, Arturo ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SKIN TOXICITY; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 0030838930     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2882     Document Type: Article

References (47)

1. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 332:901-906, 1995
2. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
3. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:71-85, 1992
4. Rivkin SE, Green S, Metch B, et al: Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study. J Clin Oncol 7:1229-1238, 1989
5. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990
6. Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15:20-25, 1988
7. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive breast cancer. N Engl J Med 330:1260-1266, 1994
8. Jones SE, Moon TE, Bonadonna G, et al: Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 10:387-395, 1987
9. Moon TE, Jones SE, Bonadonna G, et al: Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol 10:396-403, 1987
10. Buzdar AU, Kau S-W, Hortobagyi GN, et al: Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 69:448-452, 1992
11. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542-547, 1995
12. Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127-2137, 1992
13. Wood WC, Budman DR, Horzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
14. Abeloff MD, Beveridge RA, Donehower RC, et al: Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst 82:570-574, 1990
15. Hortobagyi GN, Ames FC, Buzdar AU, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507-2516, 1988
16. Hortobagyi GN, Singletary SE, McNeese MD: Treatment of locally advanced and inflammatory breast cancer, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott, 1996, pp 585-596
17. Loprinzi CL, Carbone PP, Tormey DC, et al: Aggressive combined modality therapy for advanced local-regional breast carcinoma. J Clin Oncol 2:157-163, 1984
18. Frei E III, Antman K, Teicher B, et al: Bone marrow autotransplantation for solid tumors - Prospects. J Clin Oncol 7:515-526, 1989
19. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
20. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
21. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
22. Peters WP, Berry D, Vredenburgh JJ, et al: Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥ 10 axillary lymph nodes (Duke/CALGB 8782) Proc Am Soc Clin Oncol 14:317, 1995 (abstr)
23. Somlo G, Doroshow JH, Forman SJ, et al: High-dose doxorubicin, etoposide, cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer 73:1678-1685, 1994
24. Somlo G, Doroshow JH, Lev-Ran A, et al: Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: A randomized, placebo-controlled, double-blind trial. J Clin Oncol 13:1231-1237, 1995
25. Somlo G, Doroshow JH, Forman SJ, et al: High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer 73:125-134, 1994
26. Jones RB, Holland JF, Bhardwaj S, et al: A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 5:172-177, 1987
27. Blumenschein GF, Distefano A, Firstenberg BA, et al: Response of measurable metastatic breast cancer to combination cyclophosphamide, doxorubicin, VP16 (CaVe). Proc Am Assoc Cancer Res 29:196, 1988 (abstr)
28. Sledge GW, Loehrer PJ, Roth BJ, et al: Cisplatin as first line therapy for metastatic breast cancer. J Clin Oncol 6:1811-1814, 1988
29. + selection and various schedules of stem cell reinfusion and G-CSF priming on hematopoietic recovery following high-dose chemotherapy for breast cancer. Blood 89:1521-1528, 1997
30. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
31. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
32. SAS Institute Inc: SAS Technical Report P-217, SAS/STAT Software: The PHREG Procedure Version 6. Cary, NC, SAS Institute Inc, 1991, p 63
33. Esteban JM, Somlo G: Skin biopsy in allogeneic and autologous bone marrow transplant patients: A histologic and immunohistochemical study and review of the literature. Mod Pathol 8:59-64, 1995
34. Gianni AM, Siena S, Bregni M, et al: 5-year results of high-dose sequential (HD) adjuvant chemotherapy in breast cancer with ≥ 10 positive nodes. Proc Am Soc Clin Oncol 14:90, 1995 (abstr)
35. Fay J, Jones S, Lynch J, et al: The treatment of primary breast cancer with intensive thiotepa (TPA), cyclophosphamide (CPA) and hematopoietic stem cell (HSC) transplantation - A phase II trial of the North American Marrow Transplant Group. Proc Am Soc Clin Oncol 14: 104, 1995 (abstr)
36. Somlo G, Doroshow J, Forman S, et al: High-dose chemotherapy (HDCT) and stem cell rescue (SCR) for the treatment (Rx) of primary high-risk breast cancer (HRBC): Prognositc indicators of overall survival (OS) and progression-free survival (PFS). Proc Am Soc Clin Oncol 14:113, 1995 (abstr)
37. Doroshow JH, Somlo G, Ahn C, et al: Prognostic factors predicting progression-free (PFS) and overall survival (OS) in patients (PTS) with responsive metastatic breast cancer (MBC) treated with high-dose chemotherapy (HDCT) and bone marrow stem cell reinfusion. Proc Am Soc Clin Oncol 14:319, 1995 (abstr)
38. Somlo G, Simpson J, Doroshow J, et al: Immunohistochemical (H) expression of p53, estrogen (ER) and progesterone (PR) receptors and MIB-1 as well as increased mitotic index (MI) are predictors of outcome after high-dose chemotherapy (HDCT) and stem cell rescue (SCR) for high-risk breast cancer (HRBC) patients (PTS). Proc Am Soc Clin Oncol 15:126, 1996 (abstr)
39. Bitran JD, Samuels B, Trujillo Y, et al: Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (≥ 10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 2:1509-1513, 1996
40. Rosner GL, Hargis JB, Hollis DR, et al: Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: Results from Cancer Leukemia Group B study 8541. J Clin Oncol 14:3000-3008, 1996
41. Ragaz J, Jackson S, Le N, et al: Can adjuvant locoregional radiotherapy (XRT) reduce systemic recurrences in stage I-II breast cancer patients? Recurrence analysis of the British Columbia randomized trial. Proc Am Soc Clin Oncol 15:121, 1996 (abstr)
42. → concurrent (Con) T + C as adjuvant therapy in resected node positive (+) breast cancer (NPBC). Proc Am Soc Clin Oncol 15:119, 1996 (abstr)
43. Williams SF, Mick R, Desser R, et al: High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 7:1824-1830, 1989
44. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose chemotherapy. J Clin Oncol 10:102-110, 1992
45. Dunphy FR, Spitzer G, Buzdar AU, et al: Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207-1216, 1990
46. Kennedy MJ, Beveridge RA, Rowley SD, et al: High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920-926, 1991
47. Bezwoda WR, Seymour L, Dansy RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2989, 1995